Autosomal dominant polycystic kidney disease: 2009 Update for internists

Korean Journal of Internal Medicine

Volumn 24, Issue 3, 2009, Pages 165-168

  Bennett, William M ^a  

^a LEGACY GOOD SAMARITAN HOSPITAL   (United States)

Author keywords

Genetic; Hypertension; Kidney; Polycystic kidney diseases; Tubule

Indexed keywords

RAPAMYCIN; TOLVAPTAN;

AUTOSOMAL DOMINANT DISORDER; BLOOD PRESSURE REGULATION; DISEASE COURSE; HUMAN; HYPERTENSION; INTRACRANIAL ANEURYSM; KIDNEY POLYCYSTIC DISEASE; LIVER CYST; PATHOPHYSIOLOGY; REVIEW; GENETICS; PROGNOSIS;

HUMANS; POLYCYSTIC KIDNEY, AUTOSOMAL DOMINANT; PROGNOSIS;

EID: 70449700254     PISSN: 12263303     EISSN: 20056648     Source Type: Journal    
DOI: 10.3904/kjim.2009.24.3.165     Document Type: Review

References (19)

1. Rossetti S, Consugar MB, Chapman AB, et al. Comprehensive molecular diagnostics in autosomal dominant polycystic kidney disease. J Am Soc Nephrol 2007;18:2143-2160. (Pubitemid 47041080)
2. Rossetti S, Kubly VJ, Consugar MB, et al. Incompletely penetrant PKD1 alleles suggest a role for gene dosage in cyst initiation in polycystic kidney disease. Kidney Int 2009;75:848-855.
3. Torra R, Badenas C, Darnell A, et al. Linkage, clinical features, and prognosis of autosomal dominant polycystic kidney disease types 1 and 2. J Am Soc Nephrol 1996;7:2142-2151. (Pubitemid 27468243)
4. Harris PC, Bae KT, Rossetti S, et al. Cyst number but not the rate of cystic growth is associated with the mutated gene in autosomal dominant polycystic kidney disease. J Am Soc Nephrol 2006;17:3013-3019. (Pubitemid 44707761)
5. Pei Y. A "two-hit" model of cystogenesis in autosomal dominant polycystic kidney disease? Trends Mol Med 2001;7:151-156.
6. Nauli S, Alenghat FJ, Luo Y, et al. Polycystins 1 and 2 mediate mechanosensation in the primary cilium of kidney cells. Nat Genet 2003;33:129-137. (Pubitemid 36177063)
7. Patel V, Chowdhury R, Igarashi P. Advances in the pathogenesis and treatment of polycystic kidney disease. Curr Opin Nephrol Hypertens 2009;18:99-106.
8. Grantham JJ, Torres VE, Chapman AB, et al. Volume progression in polycystic kidney disease. N Engl J Med 2006;354:2122-2130.
9. Grantham JJ, Cook LT, Torres VE, et al. Determinants of renal volume in autosomal-dominant polycystic kidney disease. Kidney Int 2008;73:108-116. (Pubitemid 350273644)
10. Pei Y, Obaji J, Dupuis A, et al. Unified criteria for ultrasonographic diagnosis of ADPKD. J Am Soc Nephrol 2009;20:205-212.
11. Huang E, Samaniego-Picota M, McCune T, et al. DNA testing for live kidney donors at risk for autosomal dominant polycystic kidney disease. Transplantation 2009;87:133-137.
12. Ecder T, Schrier RW. Cardiovascular abnormalities in autosomaldominant polycystic kidney disease. Nat Rev Nephrol 2009;5:221-228.
13. Steinman TI. Renal and cardiac effects of antihypertensive treatment with ramipril versus metoprolol in autosomal dominant polycystic kidney disease. Nephrol Dial Transplant 2008;23:431-433. (Pubitemid 351767658)
14. Grantham JJ. Clinical practice: autosomal dominant polycystic kidney disease. N Engl J Med 2008;359:1477-1485.
15. Elzinga LW, Golper T, Rashad AL, Carr ME, Bennett WM. Trimethoprim-sulfamethoxazole in cyst fluid from autosomal dominant polycystic kidneys. Kidney Int 1987;32:884-888. (Pubitemid 18015520)
16. Elzinga LW, Golper TA, Rashad AL, Carr ME, Bennett WM. Ciprofloxacin activity in cyst fluid from polycystic kidneys. Antimicrob Agents Chemother 1988;32:844-847.
17. Wilson PD. Polycystic kidney disease. N Engl J Med 2004;350:151-164.
18. Torres VE, Harris PC, Pirson Y. Autosomal dominant polycystic kidney disease. Lancet 2007;369:1287-1301. (Pubitemid 46552051)
19. Chapman AB. Approaches to testing new treatments in autosomal dominant polycystic kidney disease: insights from the CRISP and HALT-PKD studies. Clin J Am Soc Nephrol 2008;3:1197-1204.